Intra-arterial chemotherapy for advanced retinoblastoma: Is the time right for a prospective clinical trial?

Archives of Ophthalmology

Volumn 129, Issue 11, 2011, Pages 1487-1489

  Levin, Marc H ^a   Gombos, Dan S ^b   O'Brien, Joan M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; MELPHALAN; TOPOTECAN;

ADVANCED CANCER; ARTERY OCCLUSION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG FATALITY; EDITORIAL; ENUCLEATION; EYELID EDEMA; FLUOROSCOPY; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; PTOSIS; RETINA ARTERY OCCLUSION; RETINA DISEASE; RETINOBLASTOMA; STROKE; TREATMENT OUTCOME; VITREOUS HEMORRHAGE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; EYE NEOPLASMS; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; MELPHALAN; NEOPLASM SEEDING; RETINAL NEOPLASMS; RETINOBLASTOMA; VITREOUS BODY;

EID: 81355154086     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2011.304     Document Type: Editorial

References (25)

1. Hilgartner HL. Report of a case of double glioma treated with x-rays. Texas Med. 1903;18:322-323.
2. Reese AB, Hyman GA, Merriam GR Jr, Forrest AW, Kligerman MM. Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol. 1954;53(4):505-513.
3. Roarty JD, McLean IW, Zimmerman LE. Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology. 1988;95(11):1583-1587.
4. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-1267. (Pubitemid 27435614)
5. Kupfer C. Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol. 1953;36(12):1721-1723.
6. Ferris FL III, Chew EY. A new era for the treatment of retinoblastoma. Arch Ophthalmol. 1996;114(11):1412.
7. Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41-53.
8. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276-2280. (Pubitemid 44838917)
9. Jehanne M, Lumbroso-Le Rouic L, Savignoni A, et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637-643.
10. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114(7):1378-1383. (Pubitemid 47008929)
11. Reese AB, Hyman GA, Merriam GR Jr, Forrest AW, Kligerman MM. Treatment of retinoblastoma by radiation and triethylenemaline. AMA Arch Opthalmol. 1955;53(4):505-513.
12. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004;9(2):69-73. (Pubitemid 38619319)
13. Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):1398- 1404.
14. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology. 2010;117(8):1623-1629.
15. Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011;129(6):732-737.
16. Peterson EC, Elhammady MS, Quintero-Wolfe S, Murray TG, Aziz-Sultan MA. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg. 2011;114(6):1603-1608.
17. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma:, report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129(11):1399-1406.
18. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol. 2011;129(11):1399-1406.
19. Munier FL, Beck-Popovic M, Balmer A, Gaillard MC, Bovey E, Binaghi S. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma. Retina. 2011;31(3):566-573.
20. Eagle RC Jr, Shields CL, Bianciotto C, Jabbour P, Shields JA. Histopathologic observations after intra-arterial chemotherapy for retinoblastoma [published online July 11, 2011]. Arch Ophthalmol. 2011;129(11):1416-1421.
21. Vijayakrishnan R, Shields CL, Ramasubramanian A, Emrich J, Rosenwasser R, Shields JA. Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol. 2010;128(11):1427-1431.
22. Eagle RC Jr. High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med. 2009;133(8):1203-1209.
23. Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with highrisk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41-48. (Pubitemid 32096384)
24. Zhao J, Dimaras H, Massey C, et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol. 2011;29(7):845-851.
25. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol. 2003;121(8):1120-1124. (Pubitemid 36962165)